1. Albert DM, Wong VG, Henderson ES. Ocular complications of vincristine therapy. Arch Ophthalmol. 1967; 78:709–13.
Article
2. Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy: a clinical study of fifty leukemic patients. Neurology. 1969; 19:367–74.
Article
3. Wheeler DT, Fraunfelder FW. Ocular motility dysfunction associated with chemotherapeutic agents. J AAPOS. 2004; 8:15–7.
Article
4. von Noorden GK. Binocular vision and ocular motility, 5th ed. St. Louis: CV Mosby;1996; 415–22.
5. Rucker CW. The causes of paralysis of the third, fourth, and sixth cranial nerves. Am J Ophthalmol. 1966; 61:1293–8.
Article
6. Patel SV, Mutyala S, Leske DA, et al. Incidence, associations, and evaluation of sixth nerve palsy using a population-based method. Ophthalmology. 2004; 111:369–75.
Article
7. Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man: clinical, electrophysical and pathological studies. J Neurol Sci. 1970; 10:107–31.
8. Delaney P. Vincristine-induced laryngeal nerve paralysis. Neurology. 1982; 32:1285–8.
Article
9. Rosenthal S, Kaufman S. Vincristine neurotoxicity. Ann Intern Med. 1974; 80:733–7.
Article
10. McCarthy GM, Skilling JR. A prospective cohort study of the orofacial effects of vincristine neurotoxicity. J Oral Pathol Med. 1991; 20:345–9.
Article
11. Whittaker JA, Griffith IP. Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine. Br Med J. 1977; 1:1251–2.
Article
12. Norton S, Stockman JA. Unilateral optic neuropathy following vincristine chemotherapy. J Pediatr Ophthalmol Strabismus. 1979; 16:190–3.
Article
13. Mahajan SL, Ikeda Y, Myers TJ, Baldini MG. Acoustic nerve palsy associated with vincristine therapy. Cancer. 1981; 47:2404–6.
14. Lash SC, Williams CP, Marsh CS, et al. Acute sixth-nerve palsy after vincristine therapy. J AAPOS. 2004; 8:67–8.
Article
15. Toker E, Yenice O, Oğüt MS. Isolated abducens nerve palsy induced by vincristine therapy. J AAPOS. 2004; 8:69–71.
Article